DOI: 10.4244/EIJV13I17A341

Reply to the letter to the editor by Yaeger regarding the article “In vivo validation of mathematically derived fractional flow reserve for assessing haemodynamics of coronary tandem lesions”

We appreciate the interest in our article1. The author raised the issues of the driving force for myocardial flow, the flow ratio estimation, and the procedural order. Also, the author suggested that the application of the prediction model in Yaeger2 would improve the outcomes of FFR prediction.

Spaan et al3 showed that, even without collateral flows, (Pd–Pv)/(Pa–Pv) overestimates the coronary flow ratio (QS/QN) and the microvascular resistance (Rmin) increases as the distal pressure (Pd) falls. To build an equation to describe the P–Q relationship better, we introduced “R” corresponding to the inverse of the slope for Q vs. Pd–Pw, instead of using a constant microvascular resistance (Figure4 in Spaan et al3). The flow ratios to branches, in the same regard, were estimated using anatomical metrics. Because “R” in our mathematical derivation is dimensionally equivalent to the resistance in electronic circuit modelling, we called it “resistance”.

For determining the procedural order, previous studies have recommended that treatment of the stenosis with greater pressure or FFR gradient during pressure wire pullback should be prioritised4, as addressed in the introduction of our article1. Please remember that the objective of our work was to propose a better method for predicting more severe lesions.

The prediction model of Yaeger2 was examined and the outcomes are listed in Table 1. The mean error was 0.057±0.059 and the mean absolute error was 0.063±0.052. In the Appendix, please find the translation of Yaeger’s prediction model2 to the notations in our derivation.

Appendix. Translation of Yaeger’s prediction model to the notations in the derivation by Kweon et al

For simplicity, abbreviations are used as follows.

FFRapp(LM)=a

FFRtrue(LM)=b

FFRapp(LAD) =FFRtrue(LAD)=c Eq (*1)

FFRreal(LM)=d

FFRreal(LAD)=e

From the pullback measurement, FFRapp(LM) and FFRapp(LAD) are obtained. For the comparison with our mathematical model, we rephrased the equations in Yaeger2 as functions of “a” and “c” as follows.

Equation (19) in Yaeger2 is:

Using the abbreviations above, it becomes:

Eq (*2)

By multiplying both numerator and denominator by 2b, we can get:

.

By multiplying both sides by the denominator, it becomes:

a(1+b+c–bc)=2b and a(1+c)=b(ac–a+2).

Subsequently, b can be expressed as:

. Eq (*3)

Equation (23) in Yaeger2 is:

.

Using the abbreviations above, it becomes:

.

Using the expression in Eq (*3), we can get:

.

Using the notations in Yaeger2, the prediction equation for LAD treatment becomes:

.

Equation (34) for the LM treatment in Yaeger2 is:

.

Using the abbreviations above, it becomes:

.

Using the expression in Eq (*2), we can get:

e=ac.

Using the notations in Yaeger2, the prediction equation for LM treatment becomes:

FFRreal (LAD)=FFRapp (LM)×FFRtrue (LAD).

Using the notations in our derivation, the equations above are translated as follows:

for proximal treatment,

for distal treatment.

Conflict of interest statement

The authors have no conflicts of interest to declare.

Supplementary data

Both of the letters to the Editor disputing the paper, “Invivo validation of mathematically derived fractional flow reserve for assessing haemodynamics of coronary tandem lesions”1, together with all further correspondence can be found online in the Supplementary data.

To read the full content of this article, please download the PDF.

Volume 13 Number 17
Apr 20, 2018
Volume 13 Number 17
View full issue


Key metrics

On the same subject

10.4244/EIJV12I11A219 Dec 9, 2016
FFR in daily clinical practice: from “Prêt-à-Porter” to “Haute Couture”
Finet G and Rioufol G
free

Clinical research

10.4244/EIJ-D-18-00668 Oct 18, 2019
Personalised fractional flow reserve: a novel concept to optimise myocardial revascularisation
Gosling R et al
free
Trending articles
281.53

State-of-the-Art Review

10.4244/EIJ-D-21-00695 Nov 19, 2021
Transcatheter treatment for tricuspid valve disease
Praz F et al
free
243.2

State of the art

10.4244/EIJ-D-21-01117 Sep 20, 2022
Recanalisation of coronary chronic total occlusions
Di Mario C et al
free
208.35

State-of-the-Art Review

10.4244/EIJ-D-21-01034 Jun 3, 2022
Management of in-stent restenosis
Alfonso F et al
free
168.7

Translational research

10.4244/EIJ-D-21-00824 May 15, 2022
Bench test and in vivo evaluation of longitudinal stent deformation during proximal optimisation
Toth GG et al
free
167.05

Expert review

10.4244/EIJ-D-21-00690 May 15, 2022
Crush techniques for percutaneous coronary intervention of bifurcation lesions
Moroni F et al
free
151.03

State-of-the-Art

10.4244/EIJ-D-22-00776 Apr 3, 2023
Computed tomographic angiography in coronary artery disease
Serruys PW et al
free
118

Translational research

10.4244/EIJ-D-22-00718 Jun 5, 2023
Preclinical evaluation of the degradation kinetics of third-generation resorbable magnesium scaffolds
Seguchi M et al
110.35

Viewpoint

10.4244/EIJ-E-22-00007 May 15, 2022
TAVI at 20: how a crazy idea led to a clinical revolution
Eltchaninoff H et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 6.2
2022 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2023)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2024 Europa Group - All rights reserved